Megan L. Insco

Megan L. Insco

Auto-generated profile, based on publicly available information

Megan L. Insco

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in Science
Verified
Journal Article
Closed access
MIMegan L. Insco
Megan L. Insco
BABrian J. Abraham
Brian J. Abraham
SDSara J. Dubbury
Sara J. Dubbury
IKInes H. Kaltheuner
Ines H. Kaltheuner
SDSofia Dust
Sofia Dust
LZLeonard I. Zon
Leonard I. Zon
RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We found that disrupted nuclear RNA surveillance is oncogenic. Cyclin-dependent kinase 13 ( CDK13 ) is mutated in melanoma, and patient-mutated CDK13 accelerates zebrafish melanoma. CDK13 mutation causes aberrant RNA stabilization. CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Forced aberrant RNA expression accelerates melanoma in zebrafish. We found recurrent mutations in genes encoding nuclear RNA surveillance components in many malignancies, establishing nuclear RNA surveillance as a tumor-suppressive pathway. Activating nuclear RNA surveillance is crucial to avoid accumulation of aberrant RNAs and their ensuing consequences in development and disease.

28 August 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
AMAnna K Maloney
Anna K Maloney
AGAnita Giobbie-Hurder
Anita Giobbie-Hurder
NKNikita Katukota
Nikita Katukota
MFMiklos Fogarasi
Miklos Fogarasi
POPatrick A Ott
Patrick A Ott
EBElizabeth Buchbinder
Elizabeth Buchbinder
Background The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of immunosuppressive agents. There is no data on the impact of resuming nivolumab on survival following recovery from the irAE and completion of immunosuppressive treatment. Patients and methods In this retrospective analysis, we examined a cohort of patients treated with ipilimumab/nivolumab who developed irAEs requiring treatment interruption and immunosuppressive therapy. The differences in physician practice patterns at our institution allowed us to examine the survival effect of restarting single-agent nivolumab. A multivariate analysis of clinical factors associated with improved survival was performed. Results We identified 165 patients who were treated with ipilimumab/nivolumab and developed irAEs requiring treatment interruption and immunosuppressive therapy. Patients with the best overall response of progressive disease were excluded. Of the remaining 122 patients, 46 resumed single-agent nivolumab. When stratified by age and adjusted for sex, M-stage, lactate dehydrogenase (LDH), therapy duration, and irAE type, the effect of resumption of nivolumab on survival was highly significant (p=0.02). Patients who resumed nivolumab had a 68% reduction in the hazard of death compared with patients who had not yet or never resumed nivolumab (HR: 0.32, 95% CI: 0.12 to 0.84). Of the patients who resumed nivolumab, 12 (26%) patients had subsequent irAEs, with five patients having grade 3 irAEs. No grade 4 or 5 irAEs were noted. Conclusions Resuming single-agent nivolumab following a treatment interruption for ipilimumab/nivolumab-associated irAE and completion of immunosuppressive therapy increased overall survival compared with discontinuing nivolumab permanently in patients with metastatic melanoma. Toxicity observed post-resumption of single-agent nivolumab was manageable with no severe irAEs observed.

22 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSwathy Babu
Swathy Babu
JCJiajia Chen
Jiajia Chen
CBChloé S. Baron
Chloé S. Baron
KSKaiwen Sun
Kaiwen Sun
EREmily Robitschek
Emily Robitschek
MIMegan L. Insco
Megan L. Insco
Mucosal melanoma (MM) is a deadly cancer derived from mucosal melanocytes. To test the consequences of MM genetics, we develop a zebrafish model in which all melanocytes experience CCND1 expression and loss of PTEN and TP53. Surprisingly, melanoma only develops from melanocytes lining internal organs, analogous to the location of patient MM. We find that zebrafish MMs have a unique chromatin landscape from cutaneous melanomas. Internal melanocytes are labeled using a MM-specific transcriptional enhancer. Normal zebrafish internal melanocytes share a gene expression signature with MMs. Patient and zebrafish MMs show increased migratory neural crest and decreased antigen presentation gene expression, consistent with the increased metastatic behavior and decreased immunotherapy sensitivity of MM. Our work suggests that the cell state of the originating melanocyte influences the behavior of derived melanomas. Our animal model phenotypically and transcriptionally mimics patient tumors, allowing this model to be used for MM therapeutic discovery. As this is a non-MAPK driven genetically engineered model of melanoma, our work also has implications for the 15% of cutaneous melanoma patients who lack MAPK-driving mutations.

24 June 2026 in Cell Reports
Verified
Journal Article
Open access
TTTanzina Tanu
Tanzina Tanu
ACAnna M. Cox
Anna M. Cox
JKJennifer A. Karlow
Jennifer A. Karlow
PSPriyanka Sharma
Priyanka Sharma
KSKaiwen Sun
Kaiwen Sun
MIMegan L. Insco
Megan L. Insco
Endogenous retroviral (ERV) RNA is highly expressed in cancer, suggesting a selective advantage. We identify recurrent truncating mutations in ZC3H18 (Z18), a nuclear RNA surveillance factor lost in 30% of all cancers. We show that Z18 truncating mutations are oncogenic and that Z18 plays an evolutionarily conserved role in the nuclear surveillance of oncogenic ERV RNA. In zebrafish, Z18 truncation accelerates melanoma onset and selectively increases ERV RNA. Human cancer cell lines and patient tumors with Z18 mutations also upregulate ERV RNA. In engineered human melanoma cells, Z18 truncation enhances ERV RNA accumulation more than heterozygous Z18 loss, consistent with dominant-negative activity. Truncated Z18 directly stabilizes and relocalizes ERV RNA to the cytoplasm. ERV RNA expression accelerates melanoma and is required for Z18 truncation-mediated melanoma onset in zebrafish. Growth of human melanoma cells similarly depends on Z18-regulated ERV RNA. Together, these findings support Z18-regulated ERV RNA as a driver of oncogenesis.

6 November 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
KKKaram Khaddour
Karam Khaddour
RHRizwan Haq
Rizwan Haq
EBElizabeth I Buchbinder
Elizabeth I Buchbinder
DLDavid Liu
David Liu
MMMichael P Manos
Michael P Manos
MIMegan L Insco
Megan L Insco
The biological and clinical relevance of gene fusions in melanoma is unknown. Reports and preclinical data have suggested that tumor cells with specific rearrangements such as RAF1 gene fusions could be therapeutically targeted. To investigate the relevance of targeted therapy in patients with melanoma harboring RAF1 gene fusions, we reviewed records of 1268 melanoma patients with targeted sequencing data at the Dana-Farber Cancer Institute. We identified 9 cases and report here on their clinicopathologic characteristics. We describe the favorable outcome of 2 patients who received MEK inhibitor therapy, including 1 patient with a durable response. We coalesced our data with published reports of patients with RAF1 gene fusions who were treated with targeted therapy. We find that single-agent MEK inhibition has anti-tumor activity in melanoma patients harboring an RAF1 gene fusion, and we propose that patients with RAF1 gene fusions should be considered for single-agent MEK inhibitor therapy.

26 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSwathy Babu
Swathy Babu
JCJiajia Chen
Jiajia Chen
EREmily Robitschek
Emily Robitschek
CBChloé S. Baron
Chloé S. Baron
AMAlicia McConnell
Alicia McConnell
MIMegan L. Insco
Megan L. Insco
Mucosal melanoma (MM) is a deadly cancer derived from mucosal melanocytes. To test the consequences of MM genetics, we developed a zebrafish model in which all melanocytes experienced CCND1 expression and loss of PTEN and TP53. Surprisingly, melanoma only developed from melanocytes lining internal organs, analogous to the location of patient MM. We found that zebrafish MMs had a unique chromatin landscape from cutaneous melanoma. Internal melanocytes could be labeled using a MM-specific transcriptional enhancer. Normal zebrafish internal melanocytes shared a gene expression signature with MMs. Patient and zebrafish MMs have increased migratory neural crest gene and decreased antigen presentation gene expression, consistent with the increased metastatic behavior and decreased immunotherapy sensitivity of MM. Our work suggests the cell state of the originating melanocyte influences the behavior of derived melanomas. Our animal model phenotypically and transcriptionally mimics patient tumors, allowing this model to be used for MM therapeutic discovery.